ODI Pharma Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Derek Simmross

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	26.0%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Derek Simmross

no data

Permanencia

Mr. Derek Simmross serves as Chief Executive Officer and Director of ODI Pharma AB (publ). Mr. Simmross has a long background within trading and management of companies. He has experience as a Treasury adv...

ODI Pharma Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023

ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022

Less than half of directors are independent

Less than half of directors are independent

ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020

Recent updates

ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024

Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)

ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024

Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)

ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024

ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024

Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)

ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024

First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)

ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023

ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023

ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023

Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)

ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023

ODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish Market

ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022

Less than half of directors are independent

Less than half of directors are independent

ODI Pharma AB Proceeds with Its Plans and Launches Project Skin

ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020

Odi Pharma AB and Aphria Inc. Execute Supply Agreement

New 90-day low: kr4.61

New 90-day low - kr4.83

CEO

Permanencia